An advanced gene sequencing method, ribosome profiling, often referred to as Ribo-seq, has deepened our grasp of the human genome by pinpointing previously unidentified protein coding areas. This method furnishes scientists with a detailed view of protein creation in cells.
While Ribo-seq holds potential for progressing cancer studies, it presents an unconventional perspective on the locations and methods of protein generation. This calls for scientists to confirm if these regions actually code for proteins.
John Prensner, M.D., Ph.D., a pediatric neuro-oncologist at the University of Michigan Health C.S. Mott Children's Hospital, highlighted Ribo-seq's significance in studying protein generation in cancer cells. “Ribo-seq has garnered major interest for use in studying protein production in cancer cells to identify specific abnormal proteins as targets for immunotherapy or other treatment approaches,
Unlike the more conventional chemotherapy, which can result in side effects like hair loss, nausea, and vomiting, immunotherapy triggers the patient’s immune response to combat cancer cells. At the moment, however, immunotherapy is applicable to specific types of cancer. One of the goals is to leverage Ribo-seq in comprehending the proteins generated by cancer cells, with an aim to make immunotherapy available to more patients.
A closer look reveals that protein production entails two processes: transcription and translation. Ribo-seq focuses on the latter. Historically, scientists relied on RNA sequencing (RNA-seq) to determine which genes were activated to produce proteins in certain tissue samples. While RNA-seq offers a view of the translation process, Ribo-seq provides a more accurate depiction of the speed and sites of translation.
The value of Ribo-seq gets truly underscored when results from DNA sequencing need to be interpreted using reference genomes. These are digital records representing an organism’s genetic sequence. The current challenge lies in the fact that human genome reference databases often don't recognize Ribo-seq results.
Recognizing the need to improve these databases, Prensner, who specializes in the molecular foundation of pediatric brain cancers, collaborated with global researchers. The first phase of their collaborative endeavor resulted in a comprehensive catalog of 7,264 Ribo-seq Open Reading Frames, available for researchers everywhere.
To ensure the accuracy of these findings, Prensner's team combined Ribo-Seq with proteomics techniques to verify the presence of proteins within cells. Their findings, documented in Molecular & Cellular Proteomics, suggest a structured approach to categorize the newly discovered protein-coding areas. Prensner commented on the importance of having shared terminology and database resources, as it would enhance research precision.
Such enhancements to databases will not only bolster accurate gene sequencing interpretations but also amplify our understanding of human biology, particularly in cancer research, for the foreseeable future.
While Ribo-seq holds potential for progressing cancer studies, it presents an unconventional perspective on the locations and methods of protein generation. This calls for scientists to confirm if these regions actually code for proteins.
John Prensner, M.D., Ph.D., a pediatric neuro-oncologist at the University of Michigan Health C.S. Mott Children's Hospital, highlighted Ribo-seq's significance in studying protein generation in cancer cells. “Ribo-seq has garnered major interest for use in studying protein production in cancer cells to identify specific abnormal proteins as targets for immunotherapy or other treatment approaches,
Unlike the more conventional chemotherapy, which can result in side effects like hair loss, nausea, and vomiting, immunotherapy triggers the patient’s immune response to combat cancer cells. At the moment, however, immunotherapy is applicable to specific types of cancer. One of the goals is to leverage Ribo-seq in comprehending the proteins generated by cancer cells, with an aim to make immunotherapy available to more patients.
A closer look reveals that protein production entails two processes: transcription and translation. Ribo-seq focuses on the latter. Historically, scientists relied on RNA sequencing (RNA-seq) to determine which genes were activated to produce proteins in certain tissue samples. While RNA-seq offers a view of the translation process, Ribo-seq provides a more accurate depiction of the speed and sites of translation.
The value of Ribo-seq gets truly underscored when results from DNA sequencing need to be interpreted using reference genomes. These are digital records representing an organism’s genetic sequence. The current challenge lies in the fact that human genome reference databases often don't recognize Ribo-seq results.
Recognizing the need to improve these databases, Prensner, who specializes in the molecular foundation of pediatric brain cancers, collaborated with global researchers. The first phase of their collaborative endeavor resulted in a comprehensive catalog of 7,264 Ribo-seq Open Reading Frames, available for researchers everywhere.
To ensure the accuracy of these findings, Prensner's team combined Ribo-Seq with proteomics techniques to verify the presence of proteins within cells. Their findings, documented in Molecular & Cellular Proteomics, suggest a structured approach to categorize the newly discovered protein-coding areas. Prensner commented on the importance of having shared terminology and database resources, as it would enhance research precision.
Such enhancements to databases will not only bolster accurate gene sequencing interpretations but also amplify our understanding of human biology, particularly in cancer research, for the foreseeable future.